A2 Milk expands range to make milk powder with Mānuka honey

New Zealand-Australian company a2 Milk recently expanded its range by introducing a Mānuka honey milk powder to the Chinese, Australian and New Zealand markets.

The company aims to further expand into the adult nutritional powder market.

The product combines pure a2 Milk powder with Mānuka honey, sourced from New Zealand.

The product, packed by Fonterra New Zealand, comes in a 400g tin.

READ: The a2 Milk Company expands into South Korea

Mānuka honey helps improve the digestive system, it helps with sore throats and it can aid in healing wounds.

Combined with a2 Milk, it should create a more nutritious milk.

Most cows’ milk brands today contain a mix of both A1 and A2 proteins. All a2 Milk products come from cows hand-picked to naturally produce only A2 protein and no A1.

This is because, recent research suggests that the A1 protein in regular cows’ milk might cause discomfort in the stomach.

Recently, the company was also quick to pay a $20,000 fine by the Chinese Government for using a child in its advertising.

The advertisement breached Chinese advertising regulations, which state that children under 10 years old cannot be brand ambassadors.

The company used Chinese movie star Hu Ke and her son An Ji to promote the brand.

There were 29 other companies named by China’s advertising market regulator, in July, that breached child advertising regulations.

Other regulations in advertising in China include restrictions as to how companies can advertise baby formula.

For example, it is prohibited for an advertisement to claim that it is a full or partial substitute for breast milk.

The Chinese government aims to encourage breast feeding, therefore it enforces these rules.

 

 

 

 

Japanese milk company immunogenic breakthrough

Morinaga Milk Industry has announced it has attained self-affirmed GRAS (generally recognised as safe) status in the United States for LAC-Shield, a unique immunogenic ingredient. This development opens the door for manufacturers of dietary supplements, functional foods and beverages in the US to include LAC-ShieldTM in products designed to enhance immune function.

Thanks to mounting research demonstrating the positive health benefits of probiotics, the probiotics market has experienced explosive growth over the past decade. In fact, according to Nutrition Business Journal, probiotics posted 17 per cent year-over-year growth from 2015 to 2016 in the US — the highest of any supplement category. BCC Research predicts the global market will grow to US$50b (A$67.3b) in 2020, as people’s awareness of and interest in healthful products continues to increase. However, the market is evolving beyond conventional probiotics to include metabolites of probiotics and non-viable microbes — called “immunogenics” or “immunobiotics.”

LAC-Shield (Lactobacillus paracasei MCC1849), widely recognised in Japan for its ability to enhance immunity, is one such ingredient. Unlike live cultures, LAC-Shield is rendered non-viable by heat treatment. Yet LAC-Shield still induces the production of a cytokine which activates and stimulates immune function.

LAC-Shield’s immune-boosting power was recently demonstrated in a human clinical study Morinaga Milk conducted with Kyushu Women’s University, which found it can lower the risk of contracting the common cold in susceptible subjects (Murata et al., Benef Microbes. 2018, in press). Another human clinical study, reported by Maruyama et al. (Int J Food Sci Nutr. 2016), found LAC-Shield may enhance the immune responses of the flu vaccine in the elderly with immunosenescence.

One of the most noteworthy aspects of LAC-Shield is the diversity of its potential applications. Usually, probiotics are difficult to incorporate into functional foods and beverages because of their intolerance of high temperatures and moisture. However, since LAC-Shield is pasteurised, it is highly tolerant of high heat and humidity, making it easy for manufacturers to incorporate it into a wide variety of products.

“In recent years, people have been demanding additional value and health benefits from the foods they consume. LAC-Shield has excellent potential to respond to those needs in the global market,” said Ko Shiino, general manager of the International Division at Morinaga Milk. “Achieving GRAS status enables LAC-Shield to be included in a wide variety of functional foods and beverages. We will continue our efforts to gain GRAS status for other probiotics in our portfolio so that we can contribute to healthier and brighter futures of people throughout the world.”

Morinaga Milk has a solid track record with GRAS ingredients. It attained GRAS status for its flagship probiotic Bifidobacterium longum BB536 (GRAS Notice No. GRN 000268) in 2007 and for Bifidobacterium breve M-16V (GRAS Notice No. GRN 000453 and GRN 000454) in 2013. BB536 is well-known for its stability, quality and wide-ranging functional effects, as shown by 160 scientific reports, including numerous clinical studies. M-16V is well-known for its strong safety profile and its efficacy in infants, having been used in more than 120 Neonatal Intensive Care Unit (NICU) hospitals in Japan for low-birth-weight infants to support healthy growth. As a result, Morinaga Milk attained not only FDA-notified GRAS status for M-16V, but also GRAS status for infants.